Scientists at UC San Francisco have discovered how pancreatic cancer cells thrive in the lungs or liver, environments that are as distinct to cells as the ocean and desert are to animals. The spread of cancer cells to organs like these often produces the very first symptoms of pancreatic cancer. But by that time, the pancreatic cancer has spread out of control.
The findings, published May 21 in Nature, create new opportunities to treat pancreatic cancer, which is notoriously resistant to many therapies. The study was funded in part by the National Institutes of Health (NIH), the National Science Foundation (NSF), and the American Association for Cancer Research.
“It opens the door to fighting metastatic cancer growth by manipulating how cells acquire their cholesterol.”
In the study, researchers wanted to know what allowed cells to survive in one place instead of the other. To do this, they analyzed data from MetMap, a project at the Broad Institute, an independent research organization, to find pancreatic cancer cell lines that had a tendency to colonize either the lung or the liver. Then, they looked for genomic differences that could reveal why, or even how, these cells preferred one organ over the other.
Their analysis turned up a protein called PCSK9 that controls how cells obtain cholesterol. When PCSK9 levels are low, pancreatic cancer cells consume nearby cholesterol, which is abundant in the liver. When PCSK9 levels are high, the cancer cells produce their own cholesterol. They also make molecules that protect them from damage by oxygen, a perfect adaptation to survival in the lungs.
When the team forced pancreatic cancer cells that were destined for the liver to express PCSK9, the cells made a detour to the lungs.